Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxyrell is a dietary supplement developed by Pharmatoka, a French pharmaceutical company specializing in cranberry-based health products. It is formulated as a natural antioxidant supplement, primarily utilizing a standardized extract from the North American cranberry (*Vaccinium macrocarpon*). The product is designed to leverage the high concentration of proanthocyanidins (PACs) and other bioactive polyphenols found in cranberries to neutralize free radicals and mitigate oxidative stress. While Pharmatoka is best known for its urinary tract health product, Urell, Oxyrell is positioned specifically for its systemic antioxidant benefits, aiming to protect cellular components from oxidative damage. The supplement is typically administered orally and is part of Pharmatoka's broader portfolio of products derived from proprietary cranberry extraction processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxyrell.